Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source discusses the potential of topical JAK inhibitors, like tofacitinib, as effective treatments for autoimmune skin diseases, emphasizing their superior safety profile and minimal adverse effects compared to conventional systemic therapies.

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

In this case series conducted in Austrian dermatology clinics, tralokinumab was found to be a well-tolerated and effective long-term treatment for adults with moderate-to-severe atopic dermatitis, with improvements in eczema severity and symptom suppression maintained over up to three years.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

This study concluded that the best approach for detecting Androsta-1,4,6-triene-3,17-dione administration in horses is monitoring the metabolites M1b or M4 in urine, detectable up to 77 hours post-administration.

This review discusses the developments in antifungal treatments for dermatophyte infections since 2008, reporting no new oral agents but introducing newer topical options like efinaconazole and tavaborole.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

This case report describes a 29-year-old man who developed scalp abscesses due to Mycobacterium abscessus infection after receiving scalp injections for hair loss, successfully treated with antibiotics.

This study reports that combination therapy with oral steroids, anthralin, and minoxidil yielded effective cosmetic responses in 80% of patients with treatment-resistant extensive alopecia areata.

This study introduces a novel pro-drug formulation of all-trans retinoic acid that reduces skin inflammation and achieves sustained drug release over several days compared to traditional methods.

Treatment with oral terbinafine and topical enilconazole was successful in resolving a Trichophyton dermatophytosis outbreak in L'Hoest's monkeys, with complete mycological cure achieved after eight weeks.

This review provides insights and guidelines for clinicians and patients on assessing the risks and benefits of ritlecitinib for adolescents with alopecia areata, emphasizing shared decision-making and management strategies.

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

This review article compiles past and updated information on Tridax procumbens' traditional uses and chemical compounds, highlighting its diverse pharmacological activities such as wound healing, but emphasizes the need for further toxicological research.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

This case study reports that tofacitinib led to remission of psoriasis but did not improve alopecia universalis in one patient, suggesting varied responses in treating such conditions.

This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.

Ritlecitinib works well and is safe for treating alopecia areata.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study found that in a mouse model of alopecia areata, tofacitinib inhibited CD8+ T cell infiltration at hair follicles by modulating linoleic acid metabolism and magnesium pathways, offering insights into potential therapeutic strategies for the condition.

This research developed new in vitro models for high-throughput screening of drugs that could protect or restore immune privilege in hair follicles, finding that Tofacitinib was effective in preventing inflammation-related marker upregulation, while Tacrolimus and αMSH worked specifically in outer root sheath keratinocytes.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This review found insufficient evidence to determine methotrexate's effectiveness for maintaining regrowth in extensive alopecia areata, and suggests its potential role in inducing regrowth when combined with corticosteroids.

In this clinical trial, adding topical calcipotriol to intralesional triamcinolone acetonide significantly increased hair regrowth efficacy in scalp alopecia areata patches compared to steroids alone, but not in beard patches, with a lower incidence of atrophy observed.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.